TriSalus Life Sciences® Inc. (Nasdaq: TLSI), an oncology-focused company committed to improving outcomes for liver cancer patients through its advanced drug delivery technology and investigational immunotherapy nelitolimod, has entered into a strategic partnership with Geo-Med, LLC, a certified Service-Disabled Veteran-Owned Small Business (SDVOSB). This collaboration aims to expand the availability of the TriNav Infusion System (“TriNav”) to U.S. Department of Veterans Affairs (VA) medical centers across the country, increasing access to innovative treatments for veterans battling liver cancer.
On the significance of the partnership, Mary Szela, CEO and President of TriSalus, stated, “On this day honoring our veterans, we’re proud to announce this crucial collaboration to expand access to our proprietary Pressure-Enabled Drug Delivery™ (PEDD™) approach. Enabled by TriNav, this technology has the potential to improve liver cancer treatment outcomes, and we are excited to partner with Geo-Med to ensure veterans have access to this innovative system.”
Geo-Med, a key supplier to both the VA and the U.S. Department of Defense (DOD) medical facilities, brings extensive experience in delivering high-quality medical products. Their expertise in VA procurement will play a critical role in ensuring that TriNav reaches the veterans who need it most.
Hepatocellular carcinoma (HCC), the most common form of liver cancer, is up to five times more common among U.S. veterans than in the general population.1 The PEDD™ approach, delivered through TriNav, has demonstrated its ability to enhance therapeutic delivery to liver tumors, improving the precision and effectiveness of treatment while minimizing the exposure of healthy tissue to the drug. This targeted delivery could represent a significant advancement in treating liver cancer in veterans.
Mike Locke, CEO of Geo-Med, commented, “We are honored to collaborate with TriSalus to bring this groundbreaking delivery technology to veterans. Liver cancer is a particularly aggressive disease, and by expanding access to TriNav, we are offering veterans the latest advancements in cancer treatment.”
About TriSalus Life Sciences
TriSalus Life Sciences is an oncology-focused medical technology company committed to advancing drug delivery methods for liver and pancreatic cancer treatments. The company’s proprietary Pressure-Enabled Drug Delivery™ (PEDD™) platform includes two FDA-cleared devices:
- The TriNav® Infusion System, designed for hepatic arterial infusion in liver tumors.
- The Pancreatic Retrograde Venous Infusion System, designed for pancreatic tumors.
PEDD™ is a novel drug delivery approach that overcomes anatomical limitations, increasing therapeutic concentration in tumors while minimizing exposure to healthy tissues. In addition to its delivery systems, TriSalus is advancing nelitolimod, an investigational immunotherapy aimed at improving treatment efficacy by targeting the immunosuppressive tumor microenvironment.
TriSalus’s Pressure-Enabled Regional Immuno-Oncology™ (PERIO) clinical trials suggest that delivering nelitolimod via PEDD™ could offer promising immune effects, particularly in the liver and pancreas. Nelitolimod targets TLR9, a receptor present across various cancers, and aims to address immune dysfunction and delivery barriers in these organs.
Together, TriSalus’s innovative technology and therapeutic pipeline have the potential to transform the treatment landscape for liver and pancreatic cancer patients, especially veterans who face higher incidences of these diseases.
